HCP Live May 20, 2024
On May 20, 2024, the FDA announced the approval of 2 products as interchangeable biosimilars to aflibercept—the first products to receive such a designation from the FDA.
The US Food and Drug Administration has approved a pair of biosimilar products, aflibercept-jbvf and aflibercept-yszy, as interchangeable biosimilars to aflibercept (Eylea), making them the first interchangeable biosimilars to Eylea.
Announced by the FDA on May 20, 2024, the approval indicates both biosimilars for the treatment of neovascular age-related macular degeneration (nAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy. According to the FDA, both are administered as a 2 mg (0.05 mL of 40 mg/mL) injectable solution to treat patients for the aforementioned conditions according to...
Today's Sponsors
Today's Sponsor